Less than four years after a team of former Alexion Pharmaceuticals executives launched a startup to develop new therapies for severe and rare disorders, their venture is going public. Rallybio has registered an initial public offering, indicating it hopes to raise $100 million.
Rallybio’s lead drug candidate is a monoclonal antibody called RLYB212, which aims to prevent a life-threatening condition called fetal and neonatal alloimmune thrombocytopenia, or FNAIT, which causes pregnant woman to develop antibodies that attack their fetus’ platelets, creating a risk for uncontrolled bleeding.